Alclometasone Dipropionate
FDA-approved product (ointment, topical), marketed as Aclovate, Alclometasone Dipropionate.
- Registered studies
- 2
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Eye inflammation
- Skin disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Corticosteroids, moderately potent (group ii); Corticosteroids, plain
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli47.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae36.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis47.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
2registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Alclometasone Dipropionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- AsenapineExisting use: Bipolar disorder, Bipolar I disorder, Psychosis and 1 more61.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Donepezil HydrochlorideExisting use: Alzheimer disease, Dementia61.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Mobocertinib SuccinateExisting use: Neoplasm, Non-small cell lung carcinoma61.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- BaricitinibExisting use: Rheumatoid arthritis61.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more61.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Ergoloid MesylatesExisting use: Cardiovascular disease61.6% AI-predicted activityagainst M. tuberculosis2 registered studies
- Icatibant AcetateExisting use: Angioedema, Hereditary angioedema61.6% AI-predicted activityagainst M. tuberculosis33 registered studies
- Tenofovir Alafenamide FumarateExisting use: Chronic hepatitis B virus infection, Hepatitis B virus infection, HIV infection and 2 more61.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Triptorelin PamoateExisting use: Central precocious puberty, Metastatic prostate cancer, Neoplasm and 3 more61.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- IloperidoneExisting use: Psychosis, Schizophrenia61.5% AI-predicted activityagainst M. tuberculosis32 registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted61.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Bazedoxifene AcetateExisting use: Postmenopausal osteoporosis61.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO
NCT01465802 · start 2011-12-26
Registered record
- Registry ID
- NCT01465802
- Conditions
- Non Small Cell Lung Cancer (NSCLC)
- Interventions
- Dacomitinib; Dacomitinib; Doxycycline; Probiotic; Alclometasone cream
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2011-12-26
- Completion
- 2015-05-18
- Enrolment
- 236
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon Small Cell Lung Cancer (NSCLC)InterventionDacomitinib; Dacomitinib; Doxycycline; Probiotic +1 morePhasePhase 2Registry statusCompletedStudy to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream
NCT02075632 · start 2006-09
Registered record
- Registry ID
- NCT02075632
- Conditions
- Eczema; Allergy Symptoms; Psoriasis; Itch
- Interventions
- Alclometasone dipropionate cream
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2006-09
- Completion
- 2006-11
- Enrolment
- 310
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEczema; Allergy Symptoms; Psoriasis; ItchInterventionAlclometasone dipropionate creamPhasePhase 2Registry statusCompleted